FDA and Clinical Trial Data Monitoring Committees

  • Susan S. Ellenberg
  • Jay P. Siegel


Case Study Approach Interim Result Interim Data Contract Research Organization Secondary Progressive Multiple Sclerosis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    U.S. Food and Drug Administration. 1988. Guideline for the Format and Content of the Clinical and Statistical Sections of an Application. Rockville, MD: FDA. Scholar
  2. 2.
    Ellenberg SS, Geller N, Simon R, Yusuf S (eds.). 1993. Proceedings of “Practical Issues in Data Monitoring of Clinical Trials,” Bethesda, Maryland, USA, 27–28 January 1992. Stat Med 12:415–616.Google Scholar
  3. 3.
    O’Neill RT. 1993. Some FDA perspectives on data monitoring in clinical trials in drug development. Stat Med 12:601–608.CrossRefGoogle Scholar
  4. 4.
    O’Neill RT. 1993. A regulatory perspective on data monitoring and interim analysis. In Buncher CR, Tsay JY (eds.): Statistics in the Pharmaceutical Industry. Marcel Dekker, New York.Google Scholar
  5. 5.
    Title 21, US Code of Federal Regulations. Part 50.24Google Scholar
  6. 6.
    Ellenberg SS. 1997. Informed consent: Protection or obstacle? Some emerging issues. Control Clin Trials 18:628–636.CrossRefGoogle Scholar
  7. 7.
    US Food and Drug Administration. 1998. International Conference on Harmonisation: Guidance on Statistical Principles for Clinical Trials. Scholar
  8. 8.
    ICH E9 Expert Working Group 1999. ICH Harmonised Tripartite Guideline: Statistical principles for clinical trials. Stat Med 18:1905–1942.Google Scholar
  9. 9.
    US Food and Drug Administration. 2001. Guidance for Clinical Trial Sponsors on the Establishment and Operation of Clinical Trial Data Monitoring Committees. FDA, Rockville, MD. Scholar
  10. 10.
    Title 21, US Code of Federal Regulations, Parts 314.500–314.560. Scholar
  11. 11.
    Murray JM, Elashoff MR, Iacono-Connors LC, Cvetkovich TA, Struble KA. 1999. The use of plasma HIV RNA as a study endpoint in efficacy trials of antiretroviral drugs. AIDS 13:797–804.CrossRefGoogle Scholar
  12. 12.
    Ziegler EJ, Fisher CJ Jr, Sprung CL, et al. 1991. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. N Engl J Med 324:429–436.CrossRefGoogle Scholar
  13. 13.
    Siegel JP. 2002. Biotechnology and clinical trials. J Infect Dis 185:S52–S57.CrossRefGoogle Scholar
  14. 14.
    Derkx B, Wittes J, McCloskey R. 1999. Randomized, placebo-controlled trial of HA-1A, a human monoclonal antibody to endotoxin, in children with meningococcal septic shock. European Pediatric Meningococcal Septic Shock Trial Study Group. Clin Infect Dis 28:770–777.CrossRefGoogle Scholar
  15. 15.
    McCloskey RV, Straube RC, Sanders C, Smith SM, Smith CR. 1994. Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESS Trial Study Group. Ann Intern Med 121:1–5.Google Scholar
  16. 16.
    The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. 1995. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 333:1581–1588.CrossRefGoogle Scholar
  17. 17.
    PRISMS Study Group. 1998. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 352:1498–1504.CrossRefGoogle Scholar
  18. 18.
    Goodkin DE. 1998. Interferon ß therapy for multiple sclerosis. Lancet 352:1486–1500.CrossRefGoogle Scholar
  19. 19.
    U.S. Food and Drug Administration. 1998. Guidance for Industry: Providing Clinical Evidence of Effectiveness for Human Drug and Biological Products. Scholar

Copyright information

© Springer Science+Business Media, Inc. 2006

Authors and Affiliations

  • Susan S. Ellenberg
    • 1
  • Jay P. Siegel
    • 2
  1. 1.Center for Clinical Epidemiology and BiostatisticsUniversity of Pennsylvania School of MedicinePhiladelphia
  2. 2.Centocor Research and Development, Inc.Malvern

Personalised recommendations